Federal

Cardiac Cases Raise Concerns Over Drugs for ADHD

By Christina A. Samuels — February 21, 2006 4 min read
  • Save to favorites
  • Print

Dr. Steven E. Nissen said he had no preconceived notions about drugs for attention deficit hyperactivity disorder when he was asked by the U.S. Food and Drug Administration to serve on a panel charged with creating protocols for testing such drugs.

But during a presentation, Dr. Nissen and other panel members learned of 25 reports of deaths between 1999 and 2003. Several dozen other cases of cardiovascular problems among users were reported in that period, many among people with pre-existing cardiac problems.

Dr. Nissen, a Cleveland cardiologist, felt he had enough information to take action. He suggested that stimulant medications for ADHD carry a prominent warning to pediatricians, a sign that doctors should take extra care before prescribing them.

Other panel members agreed. It voted 8-7 on Feb. 9 to recommend the warning labels for some ADHD medications. The warning does not prevent doctors from prescribing medications, but is intended to ensure that doctors know that their patients truly need the drugs and are aware of the risks.

The panel’s recommendation has reverberated around the country among doctors, parents of children who have been diagnosed with the disorder, and educators.

That’s just what Dr. Nissen, the interim director of cardiovascular medicine at the Cleveland Clinic, a renowned medical facility, wanted to happen.

“I want a public dialogue between parents and teachers and doctors,” he said in an interview last week. “People deserve to know what risks they’re taking with their medications.”

A Backlash

But the panel’s recommendation has also stirred a backlash, especially from psychiatrists and family physicians who prescribe medications for ADHD. They say the FDA advisory panel overstepped its charge and is making recommendations without knowing all the facts.

“It doesn’t astonish me that they wanted to weigh in,” Dr. Robert Temple, the director of the FDA’s office of medical policy, said at a press conference called after the panel’s decision. “But it wasn’t the primary matter we wanted them to weigh in on.”

The agency is not required to accept the panel’s recommendation, but officials said they would consider it.

“Every medication has a side effect,” said Dr. Lynn Wegner, a Morrisville, N.C., pediatrician who is the chairwoman of the section on developmental and behavioral pediatrics for the American Academy of Pediatrics. “The question is whether the risk is worth the reward.”

Dr. Wegner supports more study to determine whether people who have died after taking ADHD medications may have had underlying cardiac conditions. Before that’s known, it’s impossible to say just how harmful ADHD drugs may be to a wider population, she said.

Drugs Under Scrutiny

Psychostimulants are the most widely used medications for the treatment of attention deficit hyperactivity disorder. In 2003, 2.5 million children ages 4 to 17 were receiving such medications for the disorder, according to the federal Centers for Disease Control and Prevention.

A federal Food and Drug Administration advisory panel has recommended that psychostimulants carry a prominent warning that they may cause sudden death or have serious complications.

Medication Brand Names
methylphenidate Ritalin
Concerta
Metadate
Focalin
amphetamines Adderall
Dexedrine
Dextrostat

SOURCES: U.S. Food and Drug Administration; National Resource Center on AD/HD

But she envisions that some doctors may just throw up their hands and stop prescribing the medications to avoid legal liability. When the news of the panel’s recommendations came out, Dr. Wegner said she had 20 messages on her answering machine within days from parents and patients who wanted to talk to her about them.

“The general pediatrician who’s busy and reads this article in The New York Times may say, ‘I don’t want to do this anymore,’ ” she said.

According to the U.S. Centers for Disease Control and Prevention, located in Atlanta, 2.5 million U.S. children ages 4 to 17 were receiving medication for ADHD, a condition characterized by inattention and impulsivity, in 2003. Psychostimulant medications, sold under brand names such as Ritalin, Concerta, and Adderall, are most often prescribed to treat the disorder. Many of the drugs have been around for decades; Ritalin was approved by the FDA in 1955.

According to the CDC, 4.4 million U.S. 4- to 17-year-olds have been diagnosed with ADHD by a health-care professional. In 2003, 7.8 percent of school-age children were reported to have an ADHD diagnosis by their parent. IMS Health, a Fairfield, Conn.-based pharmaceutical-information and -consulting company, said ADHD medications accounted for $3.6 billion in sales last year.

Benefits Ignored?

The medications have come under fire before, from those who say they are overprescribed and have unknown side effects. In February 2005, Canadian health authorities removed Adderall from the market over concerns about sudden deaths, but they allowed the drug to be sold six months later, in August.

Shire Pharmaceuticals, the British company that manufactures Adderall, released a statement saying that the FDA panel’s action was “unwarranted.”

Adderall “already include[s] a black-box warning in their labels for safety concerns related to amphetamine abuse or misuse,” the statement added. “The label also warns of the risk of sudden death in patients with structural cardiac abnormalities.”

Also being overlooked, the statement from Shire said, are the benefits of the medication.

Ginny Thiersch, a spokeswoman for the Landover, Md.-based group Children and Adults with Attention Deficit/Hyperactivity Disorder, or CHADD, said that the FDA panel “put the recommendation before the science.”

Now, she said, parents may be prompted to take their children off the medication without talking to their doctors, a step that Ms. Thiersch believes could have disastrous effects on such children’s classroom behavior.

Dr. Nissen, one of the first physicians to sound an alarm about Vioxx, a pain medication pulled from the market after being linked to sudden cardiac deaths, said that it’s safer for consumers to have the warnings in place, and then allow the drug companies to determine whether the warnings were unwarranted.

He said he believes that ADHD drugs are overprescribed, sometimes at the request of teachers or school administrators. Many children do benefit from ADHD drugs, he said.

“But giving it to kids with marginal symptoms, as opposed to counseling them or working with them,” Dr. Nissen said, “may not be the right thing to do.”

Related Tags:

A version of this article appeared in the February 22, 2006 edition of Education Week as Cardiac Cases Raise Concerns Over Drugs for ADHD

Events

This content is provided by our sponsor. It is not written by and does not necessarily reflect the views of Education Week's editorial staff.
Sponsor
Budget & Finance Webinar
Innovative Funding Models: A Deep Dive into Public-Private Partnerships
Discover how innovative funding models drive educational projects forward. Join us for insights into effective PPP implementation.
Content provided by Follett Learning
Budget & Finance Webinar Staffing Schools After ESSER: What School and District Leaders Need to Know
Join our newsroom for insights on investing in critical student support positions as pandemic funds expire.
This content is provided by our sponsor. It is not written by and does not necessarily reflect the views of Education Week's editorial staff.
Sponsor
Student Achievement Webinar
How can districts build sustainable tutoring models before the money runs out?
District leaders, low on funds, must decide: broad support for all or deep interventions for few? Let's discuss maximizing tutoring resources.
Content provided by Varsity Tutors for Schools

EdWeek Top School Jobs

Teacher Jobs
Search over ten thousand teaching jobs nationwide — elementary, middle, high school and more.
View Jobs
Principal Jobs
Find hundreds of jobs for principals, assistant principals, and other school leadership roles.
View Jobs
Administrator Jobs
Over a thousand district-level jobs: superintendents, directors, more.
View Jobs
Support Staff Jobs
Search thousands of jobs, from paraprofessionals to counselors and more.
View Jobs

Read Next

Federal K-12 Leaders Denounce Antisemitism But Reject That It's Rampant in Schools
Three school district leaders said they're committed to rooting out antisemitism during a hearing in Congress.
6 min read
From left, David Banks, chancellor of New York Public schools, speaks next to Karla Silvestre, President of the Montgomery Count (Md.) Board of Education, Emerson Sykes, Staff Attorney with the ACLU, and Enikia Ford Morthel, Superintendent of the Berkeley United School District, during a hearing on antisemitism in K-12 public schools, at the House Subcommittee on Early Childhood, Elementary, and Secondary Education, on May 8, 2024, on Capitol Hill in Washington.
From left, David Banks, chancellor of New York City schools, speaks next to Karla Silvestre, president of the Montgomery County, Md., school board; Emerson Sykes, staff attorney with the ACLU; and Enikia Ford Morthel, superintendent of the Berkeley Unified school district in Berkeley, Calif., during a hearing on antisemitism in K-12 public schools, at the House Subcommittee on Early Childhood, Elementary, and Secondary Education, on May 8, 2024, in Washington.
Jacquelyn Martin/AP
Federal Miguel Cardona in the Hot Seat: 4 Takeaways From a Contentious House Hearing
FAFSA, rising antisemitism, and Title IX dominated questioning at a U.S. House hearing with Education Secretary Miguel Cardona.
6 min read
Secretary of Education Miguel Cardona testifies during a House Committee on Education and Workforce hearing on Capitol Hill, Tuesday, May 7, 2024, in Washington.
U.S. Secretary of Education Miguel Cardona testifies during a House Committee on Education and Workforce hearing on Capitol Hill on May 7 in Washington.
Mariam Zuhaib/AP
Federal Arming Teachers Could Cause 'Accidents and More Tragedy,' Miguel Cardona Says
"This is not in my opinion a smart option,” the education secretary said at an EdWeek event.
4 min read
U.S. Secretary of Education Miguel Cardona speaks during Education Week’s 2024 Leadership Symposium at the Hyatt Regency Crystal City in Arlington, Va., on May 2, 2024.
U.S. Secretary of Education Miguel Cardona speaks during Education Week’s 2024 Leadership Symposium at the Hyatt Regency Crystal City in Arlington, Va., on May 2, 2024.
Sam Mallon/Education Week
Federal Opinion Should Migrant Families Pay Tuition for Public School?
The answer must reflect an outlook that is pro-immigration, pro-compassion, and pro-law and order, writes Michael J. Petrilli.
Michael J. Petrilli
4 min read
Image of a pencil holder filled with a variety of colored pencils that match the background with international flags.
Laura Baker/Education Week via Canva